Home  »  Markets   »  Is Aclaris Therapeutics Inc. (NASDAQ:ACRS) Still W...

Is Aclaris Therapeutics Inc. (NASDAQ:ACRS) Still Worth A Bite?

Aclaris Therapeutics Inc. (NASDAQ:ACRS) shares fell to a low of $20.89 before closing at $21.03. Intraday shares traded counted 0.52 million, which was 10.9% higher than its 30-day average trading volume of 578.67K. ACRS’s previous close was $21.74 while the outstanding shares total 50.34M. The firm has a beta of 0.66. The stock’s Relative Strength Index (RSI) is 36.10, with weekly volatility at 4.76% and ATR at 1.30. The ACRS stock’s 52-week price range has touched low of $1.26 and a $30.38 high. The stock traded lower over the last trading session, losing -3.27% on 05/26/21.

Investors have identified the Biotechnology company Aclaris Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.10 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Aclaris Therapeutics Inc. (ACRS) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 134.5 million total, with 14.51 million as their total liabilities.

Having a look at the company’s valuation, the company is expected to record -1.41 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ACRS sounds very interesting.

Is the stock of ACRS attractive?

In related news, Chief Legal Officer, Ali-Jackson Kamil sold 5,416 shares of the company’s stock in a transaction that recorded on May 07. The sale was performed at an average price of 23.52, for a total value of 127,392. As the sale deal closes, the Chief Legal Officer, Ali-Jackson Kamil now sold 15,000 shares of the company’s stock, valued at 351,453. Also, Chief Legal Officer, Ali-Jackson Kamil sold 15,000 shares of the company’s stock in a deal that was recorded on May 05. The shares were price at an average price of 23.98 per share, with a total market value of 359,713. Following this completion of acquisition, the Chief Legal Officer, Ali-Jackson Kamil now holds 15,000 shares of the company’s stock, valued at 355,187. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.20%.

Leave a Comment

Your email address will not be published. Required fields are marked *